Cyclophosphamide-based combination therapies for autoimmunity
- 9 August 2008
- journal article
- review article
- Published by Springer Nature in Neurological Sciences
- Vol. 29 (S2) , 233-234
Abstract
Immunomodulatory agent (IMA)-unresponsive multiple sclerosis (MS) can quickly evolve to a dramatic and irreversible disability. Treating these patients with appropriate immunosuppressive therapies can be a chance to arrest disease activity and progression. Cyclophosphamide (Cyc)-based intense immunosuppression has been successfully used to treat rapidly deteriorating, IMA-refractory MS patients. Therapeutic protocols combining Cyc and interferon beta (IFNβ) have also been successfully applied to treat IFNβ-unresponsive MS. The association of Cyc with other immunomodulatory drugs or monoclonal antibodies is currently being investigated in clinical trials aimed at treating severe forms of autoimmune diseases.Keywords
This publication has 12 references indexed in Scilit:
- The safety profile of cyclophosphamide in multiple sclerosis therapyExpert Opinion on Drug Safety, 2007
- A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon betaMultiple Sclerosis Journal, 2005
- Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon betaJournal of Neurology, 2004
- Immunosuppressive treatment in multiple sclerosisJournal of the Neurological Sciences, 2004
- Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.Journal of Clinical Investigation, 1998
- Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin‐4 production and associated eosinophiliaAnnals of Neurology, 1997
- Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4+T cells via CD40 ligandProceedings of the National Academy of Sciences, 1997
- Systemic Lupus Erythematosus: Emerging Concepts: Part 1: Renal, Neuropsychiatric, Cardiovascular, Pulmonary, and Hematologic DiseaseAnnals of Internal Medicine, 1995
- Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseasesSeminars in Arthritis and Rheumatism, 1983